Unlearn Stock

Unlearn develops machine-learning techniques specifically tailored for generating digital twins utilized in intelligent control groups for clinical trials. By employing AI-generated synthetic patient data, their technology expedites the pace of clinical trials, aiding in the swift development of new medications and facilitating healthcare providers in delivering crucial therapies to patients in a timely manner, thus potentially saving lives.